FMP
Gemini Therapeutics, Inc.
GMTX
NASDAQ
Inactive Equity
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
1.35 USD
0 (0%)
About
ceo
N/A
sector
Healthcare
industry
Biotechnology
website
https://www.geminitherapeutics.com
exchange
NASDAQ
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
CIK
0001816736
ISIN
US36870G1058
CUSIP
36870G105
Address
300 One Kendall Square
Phone
212 600 1902
Country
US
Employee
24
IPO Date
Aug 12, 2020
Summary
CIK
0001816736
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
36870G105
ISIN
US36870G1058
Country
US
Price
1.35
Beta
0
Volume Avg.
22.36k
Market Cap
25.49M
Shares
-
52-Week
1.35-24.7
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.geminitherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GMTX News
It looks like there's no news available.
